Regeneron Pharmaceuticals Inc (REGN, Financial) has recently captured the attention of investors and financial analysts alike, thanks to its solid financial standing and promising market position. Despite a slight daily loss of 0.36%, the company's stock price stands at $953.60, reflecting a positive three-month change of 1.62%. A detailed analysis, supported by the GF Score, indicates that Regeneron Pharmaceuticals Inc is poised for significant growth in the foreseeable future.
What Is the GF Score?
The GF Score is a proprietary stock performance ranking system developed by GuruFocus. It evaluates stocks based on five key aspects: financial strength, profitability, growth, GF Value, and momentum. These aspects have been backtested from 2006 to 2021, showing a strong correlation with long-term stock performance. Stocks with higher GF Scores typically yield higher returns. Regeneron Pharmaceuticals Inc boasts a GF Score of 94 out of 100, indicating a high potential for outperformance.
- Financial strength rank: 9/10
- Profitability rank: 10/10
- Growth rank: 10/10
- GF Value rank: 3/10
- Momentum rank: 9/10
Understanding Regeneron Pharmaceuticals Inc's Business
Regeneron Pharmaceuticals Inc, with a market cap of $105.07 billion and annual sales of $13.10 billion, operates at a robust operating margin of 30.45%. The company is a leader in biotechnology, focusing on developing treatments for eye disease, cardiovascular disease, cancer, and inflammation. Its key products include Eylea, Praluent, Dupixent, Libtayo, and Kevzara. Regeneron is also at the forefront of innovation through partnerships in RNAi and CRISPR-based gene editing technologies.
Financial Strength Breakdown
Regeneron Pharmaceuticals Inc's financial resilience is evident through its impressive Interest Coverage ratio of 56.1 and an Altman Z-Score of 11.02, indicating a strong buffer against financial distress. The company's strategic debt management is reflected in its Debt-to-Revenue ratio of 0.21, further solidifying its financial health.
Profitability and Growth Metrics
Regeneron Pharmaceuticals Inc excels in profitability, with a Profitability Rank of 10/10. The company's consistent operational performance is highlighted by its Predictability Rank of 4.5 stars. Growth remains a key focus, as evidenced by a 16% 3-Year Revenue Growth Rate, outperforming 68.12% of peers in the biotechnology industry. This growth trajectory is supported by a significant increase in EBITDA over recent years.
Conclusion
Considering Regeneron Pharmaceuticals Inc's robust financial strength, impressive profitability, and sustained growth metrics, the GF Score underscores the company's exceptional potential for market outperformance. Investors looking for similar opportunities can explore other high-performing companies using the GF Score Screen.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
